01/09/2015 - 1:58pm

Daiichi Sankyo Co., Limited on Friday announced that the Food and Drug Administration has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor that reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 

 

01/08/2015 - 11:53am

Impax Pharmaceuticals on Thursday announced that the U.S. Food and Drug Administration approved Rytary, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease.

01/07/2015 - 12:10pm

Researchers at the University of North Carolina at Chapel Hill and North Carolina State University have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting such lung-specific diseases as influenza, pneumonia and tuberculosis.

01/06/2015 - 1:31pm

According to the Walgreens Flu Index for the week beginning Jan. 5, Knoxville, Tenn. is the No. 1 designated market area with flu activity, followed by the Paducah, Ky. area and Chattanooga, Tenn.

01/05/2015 - 4:15pm

About half the country is experiencing high levels of flu activity.

 

01/05/2015 - 2:58pm

Keryx Biopharmaceuticals last month announced it has begun shipping Auryxia (ferric citrate) tablets to wholesalers in the United States. 

12/29/2014 - 12:26pm

Genentech last week announced that the Food and Drug Administration approved a supplemental biologics license application for Gazyva to be used in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.

12/29/2014 - 11:29am

Novo Nordisk last week announced that the Food and Drug Administration approved the company's new drug application for Saxenda, a once-daily glucagon-like peptide-1 receptor agonist used as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults.

12/29/2014 - 11:07am

Actavis and Adamas Pharmaceuticals last week announced that the Food and Drug Administration approved Namzaric. According to the companies, the drug is used to treat moderate to severe dementia of the Alzheimer's type in patients stablized on memantine hydrochloride and donepezil hydrochloride.